Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06776367 · ClinicalTrials.gov registry record
Project REMOTE (REimagining Measurements and Operations of Translational Endpoints)
A clinical trial of COVID-19, sponsored by Biomedical Advanced Research and Development Authority.
- Active
- Registry status
- 4,000
- Enrollment target
- 16
- Study locations
NCT06776367: Active study of COVID-19, sponsored by Biomedical Advanced Research and Development Authority.
NCT06776367 is a study of COVID-19 that is active but no longer recruiting, run by Biomedical Advanced Research and Development Authority. The registered enrollment target is 4,000 participants, below the 38,452-participant average among 298 other COVID-19 trials with a reported enrollment target (90% lower). The trial reports 16 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06776367, a study of COVID-19, is active but no longer recruiting, sponsored by Biomedical Advanced Research and Development Authority.
- ACTIVE NOT RECRUITING
- Registry status
- 4,000 participants
- Enrollment target
- 16
- Study locations
Study Summary
This trial is designed to assess immunological biomarkers measured from blood samples that can be used to reliably predict how well vaccines work against symptomatic COVID-19 as well as to evaluate the feasibility of remote, self-collected specimens when conducting a correlates analysis. For a lot of research studies, people need to go to the study doctor's office regularly. For this study, we want to see if it is okay that people do the study doctor visits virtually, fill out questionnaires electronically, and collect their own samples remotely. Participants will enroll in the study after receiving a COVID-19 vaccine in their community, and saliva and blood specimens will be collected at pre-defined time-points over a 12-month period. Additionally, participants will report weekly whether they experience symptoms of COVID-19, and if so, will be prompted to collect a nasal swab for testing. Most participants will complete all activities remotely and via electronic communications, but a small number will complete activities in person at the doctor's office to provide a comparison group. Samples from the study will be analyzed to determine whether the biomarkers can be measured, and data from the study will be used to evaluate the feasibility of doing the specimen and data collection without the participant going to the doctor's office in person.
Primary Outcome
Serum S protein-specific binding antibody (bAb) concentrations (peak and exposure-proximal assessments) * Serum SARS-CoV-2 specific neutralizing antibody (nAb) titers (peak and exposure-proximal assessments) * COVID-19: Virologically confirmed SARS-CoV-2 infection (by qualitative reverse transcriptase polymer chain reaction \[PCR\]), along with one or more of the following: fever, chills, cough, headache, fatigue, diarrhea, new loss of taste or smell, sore throat, congestion, runny nose, nausea
Conditions Studied
Interventions
- OTHER Remote study participation and self-collection of specimens
- OTHER Traditional clinical trial participation with clinician-collected specimens
Study Locations (16)
California
- Apex Research Group - Fair Oaks
- Wake Research Encino - Los Angeles
- Wake Research San Diego - San Diego
Georgia
- Emory University - Atlanta
- Wake Research Atlanta - Atlanta
Alabama
- Accel Research Site Networks - Birmingham CRU / Elite - Vestavia Hills
Arizona
- Desert Clinical Research - Mesa
Florida
- Research Institute of South Florida - Miami
Kansas
- Johnson County Clinical Trials (JCCT) - Lenexa
Kentucky
- Research Integrity / WCG - Owensboro
Massachusetts
- Alcanza / hyperCORE - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2024-12-20 |
| Est. Completion | 2026-07 |
What the registry record for NCT06776367 still lists
NCT06776367 is an observational study that tracks outcomes without assigning an intervention. Its 4,000 participants enrollment target places it among the larger protocols in the corpus, below the 38,452-participant average among 298 other COVID-19 trials with a reported enrollment target (90% lower).
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Remote study participation and self-collection of specimens is the first listed.
NCT06776367 lists 16 locations in 13 states (California, Georgia, Alabama).
Frequently Asked Questions
What is clinical trial NCT06776367 about?
NCT06776367 is a clinical study titled "Project REMOTE (REimagining Measurements and Operations of Translational Endpoints)". This trial is designed to assess immunological biomarkers measured from blood samples that can be used to reliably predict how well vaccines work against symptomatic COVID-19 as well as to evaluate the feasibility of remote, self-collected specimens when conducting a correlates analysis. For a lot o...
What is the current status of trial NCT06776367?
This trial is currently active not recruiting. The enrollment target is 4,000 participants. The study started on 2024-12-20. Estimated completion is 2026-07.
What conditions does trial NCT06776367 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT06776367?
The interventions under investigation include: Remote study participation and self-collection of specimens (OTHER), Traditional clinical trial participation with clinician-collected specimens (OTHER).
Who is sponsoring clinical trial NCT06776367?
This trial is sponsored by Biomedical Advanced Research and Development Authority, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06776367 being conducted?
This trial has 16 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06776367's enrollment target sits among peer trials
4,000 33rd of 298 higher than 266 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT00899301 · 4,000 participants
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI